Form 8-K Akero Therapeutics, Inc. For: Oct 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62
October 10, 2023 12:35 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).
The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More
Akero Therapeutics (AKRO) declines after efruxifermin NASH trial readout disappoints; Is it time to buy?
October 10, 2023 8:26 AM EDTShares Akero Therapeutics (NASDAQ: AKRO) declined after it reported analysis of data from its study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). The stock declined as much as 60% shortly after the data release.
The drug missed its primary endpoint but efficacy trends were positive in a tough population, and the selloff in shares could be an overreaction, said analysts at Cantor Fitzgerald.
Canaccord Genuity analysts said they would be strong buyers... More
Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'
October 10, 2023 8:21 AM EDTCanaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More
